Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Wiener Medizinische Wochenschrift (1946)|October 12, 2010
[Sentinel lymph node biopsy in breast cancer]Gero Luschin
BMC Medical Ethics|June 21, 2013
WHO-definition of health must be enforced by national law: a debateMarion Habersack, Gero Luschin
Plos One|December 7, 2013
Insecurities of women regarding breast cancer research: a qualitative studyMarion Habersack, Gero Luschin
Health Communication|March 30, 2013
Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: an online surveyGero Luschin, Marion Habersack
BMC Medical Research Methodology|March 13, 2012
Reasons for and against participation in studies of medicinal therapies for women with breast cancer: a debateGero Luschin, Marion Habersack, Irmina-Anna Gerlich
Clinical Oral Investigations|June 11, 2013
Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancerPetra Rugani, Gero Luschin, Norbert Jakse, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 12, 2008
Macro-environment of breast carcinoma: frequent genetic alterations in the normal appearing skins of patients with breast cancerFarid Moinfar, Alfred Beham, Gerhard Friedrich, et al.
The Journal of Pathology|September 19, 2002
Microsatellite analysis of breast carcinoma and corresponding local recurrencesPeter Regitnig, Renate Moser, Michael Thalhammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study GroupMichael F X Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
Breast Cancer Research and Treatment|December 26, 2007
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)Brigitte Mlineritsch, Christoph Tausch, Christian Singer, et al.
Pageof 2